Pfizer Inc.

NYSE:PFE Stok Raporu

Piyasa değeri: US$147.6b

Pfizer Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Pfizer şirketinin kazançları yıllık ortalama -25.8% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 9.7% oranında artan oldu. Gelirler yıllık ortalama 5% oranında azalan oldu. Pfizer şirketinin öz sermaye getirisi 8.3% olup, net marjı 11.8% dir.

Anahtar bilgiler

-25.80%

Kazanç büyüme oranı

-26.09%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi5.95%
Gelir büyüme oranı-5.01%
Özkaynak getirisi8.32%
Net Marj11.81%
Son Kazanç Güncellemesi29 Mar 2026

Yakın geçmiş performans güncellemeleri

Recent updates

Seeking Alpha • May 18

Why Pfizer Stock Still Looks Deeply Undervalued In 2026

Summary Marty Makary resigned from his position as FDA Commissioner on May 12, in my view, in part because of his inconsistent policy approach. The FDA leadership shake-up continues to this day, but as I'll explain below, this period of uncertainty isn't creating pressure on Big Pharma players, including Pfizer. By the way, Pfizer is still my favorite in the oncology drugs market, trading at a non-GAAP P/E ratio of 8.6x and a high 6.8% dividend yield. In Q1, Padcev sales were $591 million, up 16.3% QoQ and 38.7% YoY, mainly due to increased demand for its use in combination with Merck's Keytruda for treatment of MIBC. Next, I'llpresent five more key factors explaining why I continue to cover Pfizer with a'Strong Buy' rating. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 03

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook

Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.
Anlatı Güncellemesi • Apr 19

PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing

Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.
Anlatı Güncellemesi • Apr 05

PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating

Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.
Anlatı Güncellemesi • Mar 22

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook

Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.
Anlatı Güncellemesi • Mar 08

PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade

Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.
Anlatı Güncellemesi • Feb 21

PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating

Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.
Anlatı Güncellemesi • Feb 07

PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating

Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.
Anlatı Güncellemesi • Jan 24

PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares

Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.
Anlatı Güncellemesi • Jan 10

PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential

Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.
Analiz Makalesi • Jan 08

Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43

Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...
Anlatı Güncellemesi • Dec 25

PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead

Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.
Analiz Makalesi • Dec 18

Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...
Anlatı Güncellemesi • Dec 11

PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating

Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.
Anlatı Güncellemesi • Nov 13

PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts

Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.
Analiz Makalesi • Aug 12

Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business

NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...
Seeking Alpha • Apr 30

Pfizer's Q1 Update May Mark A Bottom In The Stock

Summary Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again. PFE stock is trading at trough valuations and at a larger-than-usual discount vs peers. So I think there is some decent margin of safety. Technical analysis vs SPX500 suggests PFE may be forming a bottom, but strong buyer signals are still absent. Read the full article on Seeking Alpha

Gelir ve Gider Dağılımı

Pfizer nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:PFE Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
29 Mar 2663,3157,47912,89410,710
31 Dec 2562,5797,74612,96410,437
28 Sep 2562,7859,79713,97310,131
29 Jun 2563,83310,72814,00510,205
30 Mar 2562,4647,86714,33310,521
31 Dec 2463,6278,02014,77110,822
29 Sep 2460,4334,27414,15510,494
30 Jun 2456,223-2,59314,13910,611
31 Mar 2455,946-28813,90810,564
31 Dec 2359,5542,13413,83610,679
01 Oct 2369,27410,46913,56111,420
02 Jul 2378,42021,49413,39411,435
02 Apr 2393,15429,03513,25811,621
31 Dec 22101,17531,36612,20011,426
02 Oct 2299,87829,95311,32511,260
03 Jul 22101,27529,48110,03811,243
03 Apr 2292,43325,4109,40010,667
31 Dec 2181,28822,4139,56210,360
03 Oct 2168,87719,4859,7149,972
04 Jul 2155,11912,23611,6769,589
04 Apr 2146,0849,03211,4549,184
31 Dec 2041,6516,63011,4188,709
27 Sep 2032,33421211,0068,084
28 Jun 2034,7376,97710,5657,727
29 Mar 2038,1379,42711,6377,716
31 Dec 1940,90510,70712,7667,721
29 Sep 1953,03916,21113,7557,891
30 Jun 1953,65612,63814,0507,948
31 Mar 1953,85911,46414,0047,914
31 Dec 1840,8253,82412,1497,713
30 Sep 1853,37323,80814,4817,827
01 Jul 1853,24422,54514,4927,686
01 Apr 1852,67321,74614,5097,673
31 Dec 1752,54621,30514,6067,645
01 Oct 1752,4719,79114,5467,843
02 Jul 1752,3478,30814,6087,861
02 Apr 1752,5987,28114,9597,826
31 Dec 1652,8247,19814,8947,858
02 Oct 1653,2436,27014,9567,652
03 Jul 1652,2867,03614,6977,797
03 Apr 1650,9927,61514,3397,787
31 Dec 1548,8516,94814,3257,646
27 Sep 1547,9228,36613,6407,366
28 Jun 1548,1968,91313,6667,135

Kaliteli Kazançlar: PFE büyük bir tek seferlik zarar ile $10.7B, 29th March, 2026 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: PFE 'nin mevcut net kar marjları (11.8%) geçen yılın (12.6%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PFE şirketinin kazançları son 5 yılda yılda 25.8% oranında azaldı.

Büyüme Hızlandırma: PFE 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: PFE geçtiğimiz yıl negatif kazanç büyümesine ( -5% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( -5% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: PFE 'nin Özsermaye Getirisi ( 8.3% ) düşük olarak değerlendiriliyor.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/24 21:36
Gün Sonu Hisse Fiyatı2026/05/22 00:00
Kazançlar2026/03/29
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Pfizer Inc. 44 Bu analistlerden 26, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
David ToungArgus Research Company
Emily FieldBarclays
Kerry HolfordBerenberg